Background: Anti-double stranded DNA antibodies are a very heterogeneous group of antibodies, quite specific for systemic lupus erythematosus. Newer technologies, such as addressable laser bead immunoassays (ALBIA), show great potential as a diagnostic application. The production of anti-double stranded DNA antibodies is often encountered in inflammatory arthritis; however, literature reports that the actual onset of drug induced lupus in patients treated with biological drugs is a rare event. False positive results for anti-double stranded DNA and anti-nucleosome antibodies detected in patients with inflammatory arthritis treated with different biologics prompted the investigation of full autoantibody profiles to evaluate each biomarker's diagnostic performance in systemic lupus erythematosus. The aim of the study was to compare the diagnostic performance of anti-double stranded DNA antibody and anti-nucleosome antibody methods and to evaluate the value of simultaneously measuring anti-double stranded DNA and anti-nucleosome antibodies, along with other anti-nuclear antibody analytes, as biomarkers for systemic lupus erythematosus, using a more appropriate control cohort including inflammatory arthritis patients with a non-clinical drug induced lupus. Methods: Anti-double stranded DNA and anti-nucleosome antibody levels were evaluated in 247 patient samples: 70 systemic lupus erythematosus, 177 disease controls (including 97 inflammatory arthritis during treatment with different biologics) using the Bio-Rad BioPlex Õ 2200. Results: Anti-nucleosome antibodies demonstrated greater clinical sensitivity and specificity than anti-double stranded DNA antibodies. At the manufacturers' cut-off range, considering the two markers as a single or combined test, the ''anti-double stranded DNA test or anti-nucleosome antibodies'' was the most sensitive combination (0.400) with the best negative likelihood ratio (0.62) and negative predictive value (0.803). Conclusion: Antinucleosome antibodies are a more sensitive and specific biomarker of systemic lupus erythematosus than anti-double stranded DNA antibodies. Anti-nucleosome antibodies and anti-double stranded DNA antibodies are independent and complementary markers of systemic lupus erythematosus diagnosis and, therefore, are strongly suggested as combined tests (positive predictive value ¼ 0.938). Moreover, the combined use of the two tests may help to overcome the decreased specificity percentage of the anti-double stranded DNA test, when considering an inflammatory arthritis cohort under biological therapies. The ALBIA method for anti-nuclear specificity detection allows a full autoantibody assessment, resulting in a much higher clinical specificity for systemic lupus erythematosus in the presence of !3 positive markers and significantly more positive likelihood ratio when !2 positive markers are present. Lupus (2018) 27, 40-48.
Introduction
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that involves almost all the organs in the human body, including the kidneys, skin, central nervous system (CNS), cardiovascular system, blood elements, joints and lungs.
The broad spectrum of clinical manifestations in SLE is accompanied by a huge number of autoantibodies and, to date, more than 100 autoantigens have been identified. 1 There is no other connective tissue disease similar to the SLE condition with regard to the number of autoantibodies found. Even though the presence of autoantibodies in SLE has been known for more than 60 years, nowadays a great effort is still being made to understand the pathogenetic, diagnostic and prognostic meaning of such autoantibodies. In particular, antinuclear antibodies (ANA), with a prevalence of 95-100%, are not specific for SLE, appearing in a wide range of rheumatic and non-rheumatic diseases. 2, 3 Anti-Ro/SSA antibodies, with a prevalence of 24-60%, show clinical associations with photosensitivity, interstitial lung disease, lymphopenia, xerophthalmia, ANA negative lupus, nephritis and neonatal lupus. 1, 4, 5 Anti-ribosomal P protein antibodies are highly specific for SLE, with a prevalence of 8-42% depending on the different ethnic group. They are more prevalent in juvenile-onset SLE, and are associated with nephritis, diffuse CNS involvement, epilepsy and psychiatric disorders. 1, 6, 7 Small nuclear ribonucleoprotein, such as anti-Sm autoantibodies, are highly specific for SLE, with a prevalence of 10-55%, and are associated with CNS involvement, a milder form of nephritis, lung fibrosis and pericarditis, while antibodies to 70 kDa protein of U1 snRNP, with a prevalence of 12-28%, are associated with Raynaud's phenomenon, a lower frequency of nephritis and anti-double stranded DNA (antidsDNA) antibodies. 1, 8, 9 The autoantibodies that bind to chromatin targets may recognize dsDNA, protein components of chromatin, mononucleosomes and macromolecular components of nucleosomes. [10] [11] [12] [13] Eukaryotic chromatin is comprised of approximately 40% DNA, 40% histones, 20% non-histone proteins, RNA and other macromolecules. The fundamental subunit of chromatin is the mononucleosome, composed of $180 base pairs of DNA, two molecules each of the core histones H2A, H2B, H3 and H4 and one of the linker histone H1. The core histone is organized as a histone octamer (containing two H2A-H2B dimers and one H3-H4 tetramer) around which 146 base pairs of DNA are wrapped (core particle). The structure is stabilized by the histone H1, which binds across the surface of the nucleosome.
14 Anti-nucleosome autoantibodies (ANuA) are mainly directed against histone epitopes localized primarily in exposed domains of native chromatin (i.e. carboxyl terminal tails of core histones), dsDNA and conformational epitopes created by the interaction between dsDNA and core histones. There is significant evidence that ANuA play an important role in the pathogenesis of SLE, being the first ones to appear in murine lupus models before the onset of any other autoantibodies, which are only later produced by B cells, stimulated by nucleosome-specific T cells through epitope spreading. 15 Moreover, in lupus glomerulonephritis, nucleosomes facilitate the binding of autoantibodies to glomerular basement membranes with an increased permeability and inflammatory response. 16, 17 It has also not been determined whether all the characteristic autoantibodies are pathogenic in SLE; in fact, most of these autoantibodies might be produced non-specifically as a result of polyclonal B cell activation. Common autoantibody-mediated mechanisms of damage in SLE include immune complex-mediated damage, cell surface binding and cytotoxicity, reactivity with autoantigens expressed on apoptotic or activated cell surface, penetration into living cells and binding to cross-reactive extracellular molecules. 18 Data from murine and human models have made clear the key role of autoantibodies in severe organ involvement, such as nephritis and neuropsychiatric dysfunctions. Historically, anti-dsDNA autoantibodies in particular were associated with renal involvement and have also been found in immune complex deposits in the glomeruli of SLE patients. 16, 17, 19, 20 Anti-dsDNA antibodies are a heterogeneous group of ANA and their target antigen is double stranded DNA. Higher titres of these antibodies are more suggestive of SLE and lower titres can be found in people without the disease. ANA screen analysis of 510 sera from healthy blood donors yielded low positive results of less than 2% for all of the autoantibodies tested (dsDNA, centromere B, chromatin, Jo1, ribosomal P, RNP 68, RNP A, Scl-70, Sm, SmRNP, SSA-52, SS-A60 and SSB). 21 Hence, the presence of antidsDNA antibodies is suggestive of SLE but an absence of these antibodies does not rule out the disease. Because of their high specificity, antidsDNA antibodies are universally used as a diagnostic criterion for SLE (40-80% of patients are positive for such antibodies) and for monitoring the clinical course of the patient, especially in the presence of an immunosuppressive treatment that reduces their production. 1, 22, 23 The 1997 revised American College of Rheumatology (ACR) criteria and the recent Systemic Lupus International Collaborating Clinics (SLICC) criteria [23] [24] [25] are still focused on the anti-dsDNA testing without considering the new knowledge on the highly divergent repertoire of molecular polynucleotide
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specificities, the divergent origins of the antibodies, the antibody affinity or avidity and the method used. 26, 27 In fact, over the last five decades, since their first description, several methods for antibodies to dsDNA have been developed and, even today, controversies on the different assays used still exist. [28] [29] [30] The radioimmunoassay was widely acclaimed as the assay of choice because the results can be correlated with global SLE activity, vasculitis and renal involvement, but it has been replaced by non-radioisotopic techniques because it is technically complex, time consuming and it cannot be applied on a large scale in the routine diagnostic setting. Actually, the most commonly used immunoassays are the Crithidia luciliae immunofluorescence test (CLIFT), the enzyme-linked immunoassay (ELISA) and the line immunoassay (LIA). Moreover, fully automated technologies have recently become available in the autoimmunity field as chemiluminescent immunoassay (CIA), 31 fluorescence enzymatic immunoassay (FEIA) and addressable laser bead immunoassays (ALBIA), with great potential as a diagnostic application. dsDNA autoantibody production can be transient or maintained as they are true autoantibodies or produced in the context of infections or drugs. Anti-dsNA antibodies have been specifically reported following treatment of inflammatory arthritis (IA) with biological therapies and they are usually of the IgM or the IgM/IgA subclasses, rarely of the IgG isotype. 32, 33 While the development of ANA and, less frequently, of anti-DNA antibodies is a common finding, the onset of ENA (extractable nuclear antigen) during anti-TNF-alpha blocker treatment is a rare event. The autoimmunity induced by anti-TNF-alpha therapy in fact differs from the autoantibody profile of spontaneous SLE, which is typically characterized by enough autoantibodies. 34, 35 Because cross-reactive natural autoantibodies of the IgM class have been described in the sera of healthy subjects and rheumatoid arthritis patients, 36, 37 these drugs can potentiate their production. Moreover, their increased presence can be linked to alterations of apoptosis [32] [33] [34] and to the release of nuclear antigens, but the incidence of induced antibodies to dsDNA is far higher than the incidence of clinical symptoms. 38 Considering the current use of biological drugs into the IA therapeutic strategies and the resultant increased number of anti-dsDNA requests as a screen for drug induced lupus (DIL), we aimed to evaluate the diagnostic performance of ANuA and antidsDNA antibodies as biomarkers for SLE, both single and combined, using a more appropriate control cohort including IA patients with a nonclinical DIL.
Material and methods

Sera
The study included 247 samples from patients suffering from SLE (n ¼ 70) as well as a control group (n ¼ 177) including 97 patients with IA, 40 patients with autoimmune thyroiditis and 40 samples from blood donors. The IA patients were under treatment with different biological agents and they didn't develop a clinical DIL in a follow up of five years according to Borchers et al. proposed diagnostic criteria. 39 The SLE diagnosis was established according to ACR criteria 24 and 19 out of 70 SLE patients additionally had a secondary antiphospholipid syndrome (APS). 40 All patients gave their informed consent to this retrospective study according to the Declaration of Helsinki and to Italian legislation (Authorization of the Privacy Guarantor No.9, December 12th, 2013). Formal ethical approval was not sought, owing to the retrospective nature of the study and the fact that it was carried out on leftover samples and because patients' records and information remained anonymous.
Methods
BioPlex2200
The BioPlex Õ 2200 (Bio-Rad, Hercules, CA, USA) System is an automated analyzer that uses multiplex bead technology (Luminex, Austin, TX, USA) to simultaneously detect antibodies to several antigens in a single tube. The BioPlex Õ 2200 ANA Screen kit is intended for the qualitative screening of ANAs, the quantitative detection of antibodies to dsDNA and the semi-quantitative detection of 10 separate antibodies (chromatin, ribosomal P, SS-A, SS-B, Sm, SmRNP, RNP, Scl-70, Jo-1 and centromere B) in human serum and/or ethylenediaminetetraacetic acid (EDTA) or heparinized plasma. Magnetic particles (8 mm diameter, carboxyl surface) are dyed with two fluorophores (classification dyes, CL1 and CL2) which emit at distinct wavelengths and adsorb significantly at 635 nm. The reporter fluorophore, B-phycoerythrin (PE), was chosen for its high molar extinction coefficient, quantum yield, resistance to photobleaching, lack of self-quenching and stability. The detector simultaneously measures light at four wavelengths; the two classification dyes, the
reporter dye and the scatter of the incident light. Following removal of excess conjugate, the magnetic beads are passed through the detector. Analyte concentration is proportional to the fluorescence intensity. Results are expressed in IU/mL for anti-dsDNA antibodies and AI (Antibody Index) for ANuA and the result interpretations established by the manufacturer are 5-9 IU/mL (indeterminate) and !10 IU/mL (positive) for anti-dsDNA antibodies and !1.0 AI (positive) for ANuA.
Indirect immunofluorescence (IIF) assay on HEp-2 cells
The ANA IIF method was performed with the Kallestad TM HEp-2 Cell Line Substrate slides (Bio-Rad, Hercules, CA, USA) on the automated slide processor PhD System (Bio-Rad Laboratories, Hercules, CA, USA). ANAs in a test sample bind to antigens in the substrate (human epithelial cells). Washing (phosphate buffered saline (PBS), pH 7.3) removes excess serum from the substrate. Fluorescein conjugated antiserum (universal fluorescein isothiocyanate) to human immunoglobulins added to the substrate attaches to the bound autoantibody. After a second washing step to remove excess conjugate, the substrate is coverslipped and viewed for fluorescent patterns with a fluorescent microscope. Observation of a specific fluorescent pattern(s) on the substrate indicates the presence of autoantibodies in the test sample. The screening sample dilution was 1/80 (samples automatically diluted by the PhD system with PBS). System and reagent quality were monitored on each run by adding two controls, one positive (homogeneous) and one negative. ANA IIF staining was graded from zero to three according the pattern intensity, using these criteria: three is brilliant apple green fluorescence; two is bright apple green fluorescence; one is lowest specific fluorescence that enables the staining to be clearly differentiated from the background fluorescence; zero is negative.
Crithidia luciliae immunofluorescence test (CLIFT)
The CLIFT was performed with the Kallestad TM Crithidia luciliae substrate slides (Bio-Rad, Hercules, CA, USA) on the automated slide processor PhD System (Bio-Rad Laboratories, Hercules, CA, USA). Autoantibodies to native DNA (dsDNA) in a test sample bind to antigens in the substrate (Crithidia luciliae). Washing (PBS, pH 7.3) removes excess serum from the substrate. Fluorescein conjugated antiserum (universal FITC to human immunoglobulins) added to the substrate attaches to the bound autoantibody. After a second washing step to remove excess conjugate, the substrate is coverslipped and viewed for fluorescent patterns with a fluorescent microscope. Observation of a specific fluorescent pattern on the substrate indicates the presence of autoantibodies in the test sample. The screening sample dilution was 1/10 (samples automatically diluted by the PhD system with PBS). System and reagent quality were monitored on each run by adding two controls, one positive (anti-dsDNA) and one negative. The sample was considered as positive when the kinetoplast was stained with a defined fluorescence.
Statistical analysis
The 
Results
The Table 1 ). At the manufacturers' cut-off range, considering the two markers as a single or combined test, the ''anti-dsDNA test or ANuA'' was the most sensitive combination (0.400) with the best LRÀ (0.62) and NPV (0.803). The second most sensitive test was the ANuA with a sensitivity, LRÀ and NPV of 0.348, 0.67 and 0.792, respectively. The combination of ''anti-dsDNA test and ANuA'' was the most specific (0.994) and had the best LRþ (37.93) and PPV (0.938), although the second best performer (ANuA) was also very specific (0.972), with a LRþ of 12.31 and a PPV of 0.828 (Table 1) . We compared the clinical features of SLE patients with the disease markers (antidsDNA antibodies, ANuA, ''anti-dsDNA test and ANuA,'' ''anti-dsDNA test or ANuA,'' antiribosomal P, CLIFT) and we found that the ''anti-dsDNA test or ANuA'' was the best combination of markers for renal disease, neurologic disorder, secondary APS, haematologic disorder, serositis, arthritis and skin involvement ( Table 2) . Only 36% (25/70) of SLE patients had a homogeneous pattern by IIF, both single or combined.
The low frequency of homogeneous pattern might
The impact of biological treatments on the anti-dsDNA and ANuA tests M Infantino et al. Figure 1 Receiver operator characteristics analysis for comparison of diagnostic performance of anti-double stranded DNA (antidsDNA) and anti-nucleosome antibodies (ANuA) as single or combined tests. The impact of biological treatments on the anti-dsDNA and ANuA tests M Infantino et al.
be partially due to the ENA antibodies overlapping in 40% of cases. The IIF ANA testing had an impact on the LRþ and LRÀ for SLE ( Figure 2) ; considering all the 13 markers in the ANA Panel of the BioPlex 2200, the highest clinical specificity for SLE was the presence of ! 3 positive markers and the best LRþ was when ! 2 positive markers were present (Table 3) .
Discussion
DNA isn't immunogenic by itself and only when bound to proteins (histones or viral proteins) can induce ANuA or anti-dsDNA response, and the DNA-histone complex (nucleosome) represents the major autoantigen. 26, 27, 41 In the last few years, several studies on ANuA showed that they can be considered a very useful diagnostic marker for SLE, a marker of lupus disease severity and a better predictor of flares in quiescent lupus. [42] [43] [44] [45] [46] Later, it was demonstrated that these autoantibodies may precede the occurrence of other nuclear antibodies in SLE, and therefore, the nucleosome represents the driving immunogen pressure in the epitope spreading phenomenon and the target of lupus specific antibodies. 47 The inclusion of ANuA testing in the new SLE diagnostic criteria is very strong debated as well as a better definition of the anti-dsDNA test and, in fact, many authors have recently questioned the validity of SLE criteria. 48 Most of the studies showed the higher diagnostic performance of the ANuA test compared to the anti-dsDNA antibodies test for SLE diagnosis. 49 In fact, according to Bizzaro et al., the ANuA test appeared to have an adequate level of diagnostic accuracy for SLE, with equal specificity (94.9% vs 94.2%), but higher sensitivity (60% vs 52%), positive likelihood ratio and diagnostic odds ratio than the anti-dsDNA antibodies test. 49 Additionally, ANuA could be one of the most sensitive markers in the diagnosis of SLE, especially in anti-dsDNA-negative patients. Moreover, Bardin et al. showed that the ALBIA method used for the simultaneous detection of both ANuA and anti-dsDNA autoantibodies increased the sensitivity for SLE from 68-70% when only one antibody was detected (anti-dsDNA or ANuA) to 78% when both antibodies were detected. 50 The use of biological drugs has revolutionized the therapeutic approach to patients with active disease who failed to respond to conventional therapy, but it also has been associated with immunogenicity and the development of autoimmunity, resulting in autoantibodies released, such as ANA, anti-ENA, anti-dsDNA and anti-cardiolipin antibodies. The production of anti-dsDNA antibodies is often encountered in IA, however the literature reports that the actual onset of DIL in patients treated with biological drugs is a rare event. Although, on one hand, there is no rationale to suggest anti-dsDNA antibody monitoring during the use of biological drugs in IA, on the other hand, in clinical practice, rheumatologists currently order the anti-dsDNA test to monitor DIL onset. This can lead to inappropriate referrals, misdiagnoses, anxiety in patients and inappropriate therapies. In the actual laboratory scenario, the source of routine samples asking for anti-dsDNA tests is even changing as the test is used both for AARD (ANA associated rheumatic diseases) and non-AARD conditions.
Additionally, a broader range of clinical specialists (gynaecologists, cardiologists, oncologist, neurologists) actually order the anti-dsDNA test, similarly to the ongoing change in ANA testing. In detail, the result will finally be that patients treated with selective biological drugs who developed antidsDNA antibodies without a DIL disease affected the anti-dsDNA post test probability, reducing its clinical specificity, due to a significant number of false positive results. In fact, our study showed a lower specificity for the anti-dsDNA test than the previous studies (89.8% versus 94.3%), 49 as we included in the control group an IA patient cohort under biological treatment in which we found 11 positive results, without clinically developing a DIL in a five year follow up. Furthermore, our data confirmed that ANuA and anti-dsDNA are independent and complementary SLE biomarkers since the best sensitivity performance was reached considering the ''anti-dsDNA test or ANuA'' combination. On the basis of the above observations, we strongly suggest the combined use of the two tests (PPV ¼ 0.938). However, one limitation of our study is the number of SLE patients studied and unfortunately, we cannot discuss the performance of other assays, in particular the gold standard Farr assay, as we used only the multiplex bead technology immunoassay BioPlex2200 (BioRad). Hence, the validity of our data is open to question and future studies are needed to confirm these observations. Departing from the canonical view of the anti-dsDNA test and with the emerging paradigm that nonAARDs are also monitored with ANAs and anti-dsDNA antibodies, we can conclude that the combined use of the tests may help to improve the clinical specificity of the anti-dsDNA test and its PPV. The impact of biological treatments on the anti-dsDNA and ANuA tests M Infantino et al.
